023160e4-1d9a-499c-9bfa-1b3aacf284f2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 43
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- INFLAMMATORY_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.370
- ANGIOGENESIS+0.350
- IL6_JAK_STAT3_SIGNALING+0.350
- TGF_BETA_SIGNALING+0.320
- KRAS_SIGNALING_UP+0.280
- ALLOGRAFT_REJECTION+0.230
- HEDGEHOG_SIGNALING+0.230
Top 10 suppressed
- MYC_TARGETS_V2-0.710
- OXIDATIVE_PHOSPHORYLATION-0.650
- MYC_TARGETS_V1-0.610
- DNA_REPAIR-0.520
- E2F_TARGETS-0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.500
- ADIPOGENESIS-0.430
- FATTY_ACID_METABOLISM-0.430
- PEROXISOME-0.420
- UV_RESPONSE_UP-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 86db93b2-14b0-4094-bd69-222582df130c | — | — | 0.941 |
| 2 | cd10f4f7-d92b-4152-8595-332686e4605a | — | — | 0.923 |
| 3 | ad478846-0a75-4081-ac09-37ee5415d9b4 | — | — | 0.919 |
| 4 | SRR4195664 | — | — | 0.916 |
| 5 | c874c481-cff8-4e2d-99b1-3b5aeaaecb8e | — | — | 0.913 |
| 6 | ec48e2b8-ca0a-40fe-a87b-f0e955466840 | — | — | 0.907 |
| 7 | 5abd486a-6aed-4dcf-a2a2-2537af6cdd9c | — | — | 0.905 |
| 8 | a307b24f-4caa-403a-8313-2a4604f2079a | — | — | 0.900 |
| 9 | SRR25043620 | — | — | 0.884 |
| 10 | AUR-AE6X-TTP1-A-1-0-R-A741-41 | — | D | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.110 | Idelalisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |